According to a report by The Guardian on January 2nd, the UK has approved the sale of a smoking cessation drug called Cytisine, which could play a significant role in helping people quit smoking.
Even though many smokers have turned to nicotine alternative products that are safer than cigarettes, doctors have discovered a drug called cytisine (a natural ingredient found in the seeds of the golden chain tree) that can help smokers quit their addiction, with a success rate of more than double. This drug has been in use in Central and Eastern Europe for decades but is not available in most countries, including the United States. Recently, it gained approval from regulatory authorities in the United Kingdom and is expected to hit the market at the end of this month.
Argentinian researchers conducted a thorough analysis of 12 randomized controlled trials comparing the success rates of smokers using Cytisine, a placebo, another smoking cessation drug called Champix, or nicotine replacement therapies such as patches or nicotine pouches.
Researchers have discovered that Cytisine, a plant alkaloid, is more than twice as effective as a placebo. Several studies under review indicate that this medication has similarities to Varenicline and might be more effective than nicotine replacement therapy.
According to Argentine toxicologist Omar, "Smoking is considered a major preventable cause of death worldwide. Nicotine may become one of the important solutions to address this issue."
The alkaloid vincamine will be available on the market in the UK as a prescription drug by the end of January. However, the cost of a 25-day treatment with 100 pills is £115, which may hinder certain regions from including this medication as part of their healthcare services for the public.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
